A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.
A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)
Inclusion Criteria:
Exclusion Criteria:
Tygerberg, Cape Town 7505, South Africa
Gatesville, Cape Town, 7764, South Africa